Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8829002 | Progrès en Urologie - FMC | 2018 | 4 Pages |
Abstract
Immune checkpoint inhibitors have recently become an important step for the treatment of multiple cancers. The two main drugs have the ability to reactivate the immune system against tumor cells. They can also be responsible for a lot of side effects, among which few endocrine related side effects. With anti-CTLA4, studies showed mostly hypophysitis and with anti-PD-(L)1Â blockade thyroid dysfunction was mainly observed. In addition, some type 1Â diabetes mellitus have been observed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
S.J. Drouin, E. Kuhn,